Gold­man Sachs backs clin­i­cal tri­al ser­vices in the cloud with $230M eq­ui­ty play amid de­cen­tral­ized study craze

The fo­cus on de­cen­tral­ized clin­i­cal tri­als dur­ing the Covid-19 pan­dem­ic has shak­en up the con­tract re­search space and spurred some mas­sive val­u­a­tions and deals along the way. Now, a com­pa­ny work­ing in cloud-based tri­al ser­vices on the cut­ting edge of the field has snared a ma­jor in­vest­ment from a lead­ing Wall Street banker.

4G Clin­i­cal, a ser­vices firm that pro­vides cloud-based ran­dom­iza­tion and clin­i­cal tri­al ser­vices, has bagged a $230 mil­lion eq­ui­ty in­vest­ment from Gold­man Sachs as it looks to add jet fu­el to its glob­al ex­pan­sion plans, the com­pa­ny said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER